Detection of a Microsomal Antigen and Its Antibody in Human Liver Diseases

1979 ◽  
Vol 59 (4) ◽  
pp. 459-464 ◽  
Author(s):  
E. Penner ◽  
S.O. Emejuaiwe ◽  
F. Milgrom
2015 ◽  
Vol 62 (6) ◽  
pp. 1430-1437 ◽  
Author(s):  
Laurence Amiot ◽  
Nicolas Vu ◽  
Michel Samson
Keyword(s):  

2013 ◽  
Vol 305 (5) ◽  
pp. G364-G374 ◽  
Author(s):  
Rana L. Smalling ◽  
Don A. Delker ◽  
Yuxia Zhang ◽  
Natalia Nieto ◽  
Michael S. Mcguiness ◽  
...  

The molecular mechanisms behind human liver disease progression to cirrhosis remain elusive. Nuclear receptor small heterodimer partner (SHP/ Nr0b2) is a hepatic tumor suppressor and a critical regulator of liver function. SHP expression is diminished in human cirrhotic livers, suggesting a regulatory role in human liver diseases. The goal of this study was to identify novel SHP-regulated genes that are involved in the development and progression of chronic liver disease. To achieve this, we conducted the first comprehensive RNA sequencing (RNA-seq) analysis of Shp−/− mice, compared the results with human hepatitis C cirrhosis RNA-seq and nonalcoholic steatohepatitis (NASH) microarray datasets, and verified novel results in human liver biospecimens. This approach revealed new gene signatures associated with chronic liver disease and regulated by SHP. Several genes were selected for validation of physiological relevance based on their marked upregulation, novelty with regard to liver function, and involvement in gene pathways related to liver disease. These genes include peptidoglycan recognition protein 2, dual specific phosphatase-4, tetraspanin 4, thrombospondin 1, and SPARC-related modular calcium binding protein-2, which were validated by qPCR analysis of 126 human liver specimens, including steatosis, fibrosis, and NASH, alcohol and hepatitis C cirrhosis, and in mouse models of liver inflammation and injury. This RNA-seq analysis identifies new genes that are regulated by the nuclear receptor SHP and implicated in the molecular pathogenesis of human chronic liver diseases. The results provide valuable transcriptome information for characterizing mechanisms of these diseases.


Life Sciences ◽  
1999 ◽  
Vol 65 (5) ◽  
pp. 557-563 ◽  
Author(s):  
Katsuhiro Kotake ◽  
Toshiaki Nonami ◽  
Tsuyoshi Kurokawa ◽  
Akimasa Nakao ◽  
Taro Murakami ◽  
...  

Biomarkers ◽  
2002 ◽  
Vol 7 (2) ◽  
pp. 174-187 ◽  
Author(s):  
Shelley S. Sehnert ◽  
Long Jiang ◽  
James F. Burdick ◽  
Terence H. Risby

2012 ◽  
Vol 92 (4) ◽  
pp. 1515-1542 ◽  
Author(s):  
Shelly C. Lu ◽  
José M. Mato

S-adenosylmethionine (AdoMet, also known as SAM and SAMe) is the principal biological methyl donor synthesized in all mammalian cells but most abundantly in the liver. Biosynthesis of AdoMet requires the enzyme methionine adenosyltransferase (MAT). In mammals, two genes, MAT1A that is largely expressed by normal liver and MAT2A that is expressed by all extrahepatic tissues, encode MAT. Patients with chronic liver disease have reduced MAT activity and AdoMet levels. Mice lacking Mat1a have reduced hepatic AdoMet levels and develop oxidative stress, steatohepatitis, and hepatocellular carcinoma (HCC). In these mice, several signaling pathways are abnormal that can contribute to HCC formation. However, injury and HCC also occur if hepatic AdoMet level is excessive chronically. This can result from inactive mutation of the enzyme glycine N-methyltransferase (GNMT). Children with GNMT mutation have elevated liver transaminases, and Gnmt knockout mice develop liver injury, fibrosis, and HCC. Thus a normal hepatic AdoMet level is necessary to maintain liver health and prevent injury and HCC. AdoMet is effective in cholestasis of pregnancy, and its role in other human liver diseases remains to be better defined. In experimental models, it is effective as a chemopreventive agent in HCC and perhaps other forms of cancer as well.


2010 ◽  
Vol 2010 ◽  
pp. 1-6 ◽  
Author(s):  
Shi Yin ◽  
Bin Gao

Toll-like receptor 3 (TLR3) is a member of the TLR family that can recognize double-stranded RNA (dsRNA), playing an important role in antiviral immunity. Recent studies have shown that TLR3 is also expressed on parenchymal and nonparenchymal cells in the liver as well as on several types of immune cells. In this review, we summarize the role of TLR3 in liver injury, inflammation, regeneration, and liver fibrosis, and discuss the implication of TLR3 in the pathogenesis of human liver diseases including viral hepatitis and autoimmune liver disease.


Sign in / Sign up

Export Citation Format

Share Document